Disease Landscape and Forecast Insights

Clarivate Epidemiology’s coverage of ovarian cancer comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the diagnosed events of ovarian cancer…

Clarivate Epidemiology’s coverage of ovarian cancer comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the incidence of ovarian cancer for each…

Clarivate Epidemiology’s coverage of ovarian cancer comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of ovarian cancer for each…

The ovarian cancer treatment landscape is rapidly evolving, largely due to the introduction of the angiogenesis inhibitor bevacizumab and the PARP inhibitors Lynparza (AstraZeneca / Merck & Co.),…

The ovarian cancer market in China is poised to experience substantial market growth over the 2021-2031 forecast period. For patients with ovarian cancer, chemotherapy regimens remain the go-to…

The ovarian cancer market in China is poised to experience substantial market growth over the 2021-2031 forecast period. For patients with ovarian cancer, chemotherapy regimens remain the go-to…

The treatment of ovarian cancer has historically been dominated by chemotherapy, but angiogenesis and PARP inhibitors are optimizing treatment options. The regulatory approvals of AstraZeneca /…

The treatment of ovarian cancer has historically been dominated by chemotherapy, but angiogenesis and PARP inhibitors are optimizing treatment options. The regulatory approvals of AstraZeneca /…

KEY BENEFITS AND USES Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting. Drill down into physicians’ treatment sequences and understand whom to…

The ovarian cancer treatment algorithm is rapidly evolving. For decades, chemotherapy was the standard of care, but with the introduction of Roche / Genentech / Chugai’s angiogenesis inhibitor…

KEY BENEFITS AND USES Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting. Drill down into physicians’ treatment sequences and understand who to…

The ovarian cancer treatment algorithm is rapidly evolving. For decades, chemotherapy was the standard of care, but now, with the introduction of Roche/Genentech/Chugai’s Avastin and three PARP…